Valneva SE (VALN) Capital Expenditures (2021 - 2026)
Valneva SE (VALN) posted quarterly Capital Expenditures of -$281074.7 for Q1 2026, up 82.38% year-on-year from -$154112.9 in Q1 2025, and down 103.19% on a QoQ basis from $8.8 million in Q4 2025.
Valneva SE (VALN) Capital Expenditures (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Capital Expenditures for 6 consecutive years, with -$281074.7 the latest figure, recorded in Q1 2026.
- Quarterly Capital Expenditures rose 82.38% year-over-year to -$281074.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (down 67.13% YoY) and the FY2025 annual result came in at $5.0 million, down 68.12% from the prior year.
- Capital Expenditures eased to -$281074.7 in Q1 2026 per VALN's latest filing, from $8.8 million in the prior quarter.
- Over the last five years, Capital Expenditures for VALN reached as high as $8.1 billion in Q3 2023 and fell as low as -$8.1 billion in Q2 2023.
- A 5-year average of $4.1 million and a median of -$1.4 million in 2025 frame the typical range for Capital Expenditures.
- The largest YoY upside for Capital Expenditures was 109815.52% in 2023 against a maximum downside of 108932.34% in 2023.
- Year by year, Capital Expenditures stood at $58.9 million in 2022, then plunged by 56.33% to $25.7 million in 2023, then grew by 5.69% to $27.2 million in 2024, then sank by 67.51% to $8.8 million in 2025, then tumbled by 103.19% to -$281074.7 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$281074.7, $8.8 million, and -$760153.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -281,074.70 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -281,074.70 |
| Mar 31, 2026 | -281,074.70 |
| Dec 31, 2025 | 8.82 Mn |
| Dec 31, 2025 | 8.82 Mn |
| Sep 30, 2025 | -760,153.45 |
| Sep 30, 2025 | -760,153.45 |
| Jun 30, 2025 | -1.44 Mn |
| Jun 30, 2025 | -1.44 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | 27.16 Mn |
| Dec 31, 2024 | 27.16 Mn |
| Sep 30, 2024 | -6.72 Mn |
| Sep 30, 2024 | -6.72 Mn |
| Jun 30, 2024 | 448,353.98 |
| Jun 30, 2024 | 448,353.98 |
| Mar 31, 2024 | -5.12 Mn |
| Mar 31, 2024 | -5.12 Mn |
| Dec 31, 2023 | 25.70 Mn |
| Dec 31, 2023 | 25.70 Mn |